Fig. 8.
iDR-NC/neoantigen as potent nanovaccines for neoantigen-specific tumor immunotherapy. 1 × 105 MC38 cells were i.v. injected into C57BL/6 mice, and mice were treated by s.c. injection of CpG/shRNAStat3/neoantigen iDR-NCs (2 nmol CpG equivalents, 17 μg Adpgk) at the tail base on days 10, 16, and 22. a Representative PET-CT images showing the MC38 tumor deposited in lungs on day 40. Mice were randomly picked from the group of PBS-treated mice for PET-CT. Tumor, as well as heart and bladder were illuminated by FDG. Arrow heads mark tumor nodules. H heart, B bladder. b Representative photographs (scale bar: 1 cm.), c weights, and d %ID of FDG of lungs and tumors from as-treated mice on day 40 post tumor inoculation. T tumor, L lung. (**p < 0.01; ***p < 0.001; ns: not significant; n = 6; one-way ANOVA with Bonferroni post-hoc test). Data represent mean ± s.e.m.